Daily MedNews
Printable Version   Email to a friend

Clinical Trials Update: Sept. 4, 2008

-- Here are the latest clinical trials, courtesy of CenterWatch:

Melanoma

If you are 18 or older, have histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin, and have a life expectancy of greater than 12 weeks, you may qualify for this study.

The research site is in Charlotte, N.C.

More information

Please see http://www.centerwatch.com/patient/studies/cat791.html.

-----

Diabetes Mellitus, Type 2

If you are aged 18 to 75, have type 2 diabetes, and have been treated with pioglitazone and metformin for at least 12 weeks prior to screening, you may qualify for this study.

The research site is in Wheatridge, Colo.

More information

Please see http://www.centerwatch.com/patient/studies/cat603.html.

-----

Anemia

If you are a female with iron deficiency anemia, you may qualify for this study.

The research site is in Billings, Mont.

More information

Please see http://www.centerwatch.com/patient/studies/cat373.html.

-----

Copyright 2008 CenterWatch. All rights reserved.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 20, 2008
Audience: Consumers, endocrinological healthcare professionals [Posted 11/20/2008] Animas Corporation and FDA informed consumers...
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
November 12, 2008
Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an...
More...
Latest Drug Information Updates

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

More...